The first 10 drugs that could be subject to US Medicare drug price negotiations have generally had lengthy commercial lives, underscoring one of the predominant arguments industry critics have pointed to as motivation for implementing new US drug-pricing policies.
Together, the 10 drugs identified in an analysis published on 29 March in the Journal of Managed Care and Specialty Care will have had an average commercial
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?